<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122741</url>
  </required_header>
  <id_info>
    <org_study_id>Cardio1</org_study_id>
    <nct_id>NCT05122741</nct_id>
  </id_info>
  <brief_title>Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction</brief_title>
  <acronym>BETA-MI</acronym>
  <official_title>Modulation of the WNT/Beta-Catenin Pathway in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Natasha Irrera</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gianluca Di Bella</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Antonio Micari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roberto Licordari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Francesco Squadrito</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, observational controlled cohort study designed to&#xD;
      describe the role of WNT/B-catenin signaling and adenosine system after an acute myocardial&#xD;
      infarction, correlating it with clinical markers of fibrosis/remodeling (primary objective).&#xD;
      The modulation of the aforementioned molecular patterns will also be evaluated in light of&#xD;
      the type of P2Y12 inhibitor implemented (ticagrelor or prasugrel) to identify variations in&#xD;
      response (secondary objective).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 100 patients will be enrolled in the study, 80 with clinical presentation of acute&#xD;
      myocardial infarction and eligible for treatment with either prasugrel or ticagrelor, and a&#xD;
      control cohort of 20 patients with stable coronary artery disease, matched for age, sex and&#xD;
      major risk factors, and with no history of prior myocardial infarction.&#xD;
&#xD;
      The study has been approved by the local ethics committee on 22/09/2021. Pre-enrollment&#xD;
      screening will start from 01/11/2021. Blood samples will be obtained at 5 time-points: before&#xD;
      and immediately after coronary revascularization (PCI) through the arterial introducer, and&#xD;
      in the ward / clinic at a distance of 3, 5 days and 45±15 days from the procedure during&#xD;
      normal routine examinations.&#xD;
&#xD;
      These will be used to study the expression of messenger RNA encoding for beta-catenin and to&#xD;
      dose concentrations of beta-catenin, adenosine and cyclic adenosine monophosphate (cAMP) on&#xD;
      serum. The extraction of RNA from blood samples will be carried out with a Real-time PCR&#xD;
      method and the determination of molecules using ELISA colorimetric method, using specific&#xD;
      kits.&#xD;
&#xD;
      Clinical-laboratory markers of left ventricular remodeling such as NT-proBNP, hsTnT,&#xD;
      C-reactive protein, CK-MB, 12-lead ECG, transthoracic echocardiogram and cardiac magnetic&#xD;
      resonance imaging, will be evaluated during hospitalization (at 3 and 5 days) and at the&#xD;
      control visit (at 45 ± 15 days) as per standard clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>45 Days</target_duration>
  <primary_outcome>
    <measure>Correlation between WNT/B-catenin levels and NTproBNP in patients presenting with acute myocardial infarction</measure>
    <time_frame>Measured at 5 days after PCI</time_frame>
    <description>NTproBNP as per center standard dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between WNT/B-catenin levels and and left ventricular ejection fraction in patients presenting with acute myocardial infarction</measure>
    <time_frame>Measured at 5 days after PCI</time_frame>
    <description>Left ventricular ejection fraction will be measured with transthoracic Echocardiography at the specified timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between WNT/B-catenin levels and and extent of myocardial necrosis in patients presenting with acute myocardial infarction</measure>
    <time_frame>Measured at 5 days after PCI</time_frame>
    <description>Extent of myocardial necrosis will be measured with Carciac Magnetic Resonance Imaging at the specified timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between in hospital WNT/B-catenin levels and NTproBNP at follow-up in patients presenting with acute myocardial infarction</measure>
    <time_frame>Measured at 45 day after PCI</time_frame>
    <description>NTproBNP as per center standard dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between in-hospital WNT/B-catenin levels and left ventricular ejection fraction at follow-up in patients presenting with acute myocardial infarction</measure>
    <time_frame>Measured at 45 day after PCI</time_frame>
    <description>Left ventricular ejection fraction will be measured with transthoracic Echocardiography at the specified timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between in-hospital WNT/B-catenin levels and extent of myocardial fibrosis at follow-up in patients presenting with acute myocardial infarction</measure>
    <time_frame>Measured at 45 day after PCI</time_frame>
    <description>Extent of myocardial fibrosis will be measured with Carciac Magnetic Resonance Imaging at the specified timepoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in WNT/B-catenin levels according to clinical presentation</measure>
    <time_frame>At baseline, 3, 5 and 45 day after PCI</time_frame>
    <description>Differences in results of activation of these molecular pathways in patients presenting with acute myocardial infarction and those selected in the control group by age, sex and risk factor matching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in WNT/B-catenin levels in patients treated with ticagrelor or prasugrel</measure>
    <time_frame>At baseline, 3, 5 and 45 day after PCI</time_frame>
    <description>Differences in results of activation of these molecular pathways in patients treated with ticagrelor or prasugrel presenting with acute myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in WNT/B-catenin levels in patients treated with or without Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors</measure>
    <time_frame>At baseline, 3, 5 and 45 day after PCI</time_frame>
    <description>Differences in results of activation of these molecular pathways in patients treated or not treated with Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors after acute myocardial infarction</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Myocardial Fibrosis</condition>
  <condition>Myocardial Remodeling, Ventricular</condition>
  <arm_group>
    <arm_group_label>Acute Myocardial Infarction</arm_group_label>
    <description>80 patients with clinical presentation of acute myocardial infarction undergoing primary percutaneous coronary intervention and eligible for dual antiplatelet therapy (DAPT) with either prasugrel or ticagrelor on top of aspirin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Coronary Syndrome</arm_group_label>
    <description>20 patients with stable coronary artery disease with an indication, according to current guidelines, to percutaneous coronary intervention and subsequent DAPT with aspirin and clopidogrel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2Y12 Potent Inhibitor + Aspirin for STEMI patients</intervention_name>
    <description>Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)</description>
    <arm_group_label>Acute Myocardial Infarction</arm_group_label>
    <other_name>DAPT with Potent P2Y12i</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel + Aspirin for CCS patients</intervention_name>
    <description>Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)</description>
    <arm_group_label>Chronic Coronary Syndrome</arm_group_label>
    <other_name>DAPT with Clopidogrel</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be used to study:&#xD;
&#xD;
        -  serum concentrations of Adenosine, Beta-Catenin, cAMP&#xD;
&#xD;
        -  expression mRNAs encoding for Beta-Catenin.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients planned to undergo percutaneous coronary&#xD;
        revascularization. A total of 100 patients will be enrolled in the study, 80 with clinical&#xD;
        presentation of acute myocardial infarction with an indication for primary percutaneous&#xD;
        coronary intervention and eligible for treatment with either prasugrel or ticagrelor, and a&#xD;
        control cohort of 20 patients with stable coronary artery disease and no history of prior&#xD;
        myocardial infarction who are not indicated for treatment with potent P2Y12 inhibitors.&#xD;
&#xD;
        To ensure comparability the study and control groups, the control cohort will be matched to&#xD;
        exclude a potential confounder effect of age, sex and other established risk factors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with anterior ST segment elevation acute myocardial infarction undergoing&#xD;
             coronary angiography and interventional treatment.*&#xD;
&#xD;
             * Patients with chronic coronary syndrome matched by age, sex and risk factors will&#xD;
             also be screened and included as per study design.&#xD;
&#xD;
          -  Patients with an indication to potent P2Y12 inhibitor therapy (i.e. ticagrelor or&#xD;
             prasugrel) for acute myocardial infarction.&#xD;
&#xD;
          -  Population equally amenable to ticagrelor or prasugrel therapy according to the&#xD;
             italian drug instruction of use (IFU)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a poor prognosis (less than 12 months)&#xD;
&#xD;
          -  Patients admitted with cardiogenic shock or advanced cardiac failure (NYHA 4)&#xD;
&#xD;
          -  Patients pre-treated before coronary angiography or in chronic therapy with a P2Y12&#xD;
             inhibitor&#xD;
&#xD;
          -  Patients undergoing a medical only approach without percutaneous myocardial&#xD;
             revascularization&#xD;
&#xD;
          -  Patients undergoing surgical coronary revascularization&#xD;
&#xD;
          -  Patients with prior history of myocardial infarction or prior coronary&#xD;
             revascularization.&#xD;
&#xD;
          -  Patients with contraindications or intolerance to antiplatelet therapy (ticagrelor,&#xD;
             prasugrel, clopidogrel or cardioaspirin)&#xD;
&#xD;
          -  Patients scheduled for a treatment with with cangrelor or GPIIb/IIIa inhibitors&#xD;
&#xD;
          -  Patients with active bleeding at the time of inclusion&#xD;
&#xD;
          -  Hemorrhagic diathesis&#xD;
&#xD;
          -  Confirmed history of renal failure with glomerular filtration rate of &lt;30ml/min&#xD;
&#xD;
          -  Severe hepatopathy&#xD;
&#xD;
          -  Patients treated or scheduled for treatment with oral anticoagulant therapy&#xD;
&#xD;
          -  Active cancer or diagnosis any proliferative disease within 5 years.&#xD;
&#xD;
          -  Prior TIA or stroke (ischemic or hemorrhagic)&#xD;
&#xD;
          -  Age &gt;75 years&#xD;
&#xD;
          -  Weight &lt;60kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francesco Costa</last_name>
    <phone>+390902212341</phone>
    <email>dottfrancescocosta@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Policlinico G. Martino</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Francesco Costa</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Beta-Catenin</keyword>
  <keyword>WNT Signaling pathway</keyword>
  <keyword>Adenosine systems</keyword>
  <keyword>Dual Antiplatelet Therapy</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Myocardial Fibrosis</keyword>
  <keyword>Clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

